Gralow J.R. Burstein H.J. Wood W. et al.

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

J Clin Oncol. 26: 814-819Fernandez-Martinez A. Krop I.E. Hillman D.W. et al.

Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer.

J Clin Oncol. 38: 4184-4193Sikov W.M. Berry D.A. Perou C.M. et al.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

J Clin Oncol. 33: 13-21Geyer C.E. Sikov W.M. Huober J. et al.

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.

Ann Oncol. 33: 384-394Boughey J.C. Suman V.J. Mittendorf E.A. et al.

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

JAMA. 310: 1455-1461Kuehn T. Bauerfeind I. Fehm T. et al.

Sentinel lymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Lancet Oncol. 14: 609-618Boileau J.F. Poirier B. Basik M. et al.

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

J Clin Oncol. 33: 258-264von Minckwitz G. Untch M. Blohmer J.U. et al.

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

J Clin Oncol. 30: 1796-1804Cortazar P. Zhang L. Untch M. et al.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Lancet. 384 (): 164-172https://doi.org/10.1016/S0140-6736(13)62422-8Symmans W.F. Peintinger F. Hatzis C. et al.

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

J Clin Oncol. 25: 4414-4422Symmans W.F. Wei C. Gould R. et al.

Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype.

J Clin Oncol. 35: 1049-1060

Practical Approach to Triple-Negative Breast Cancer.

J Oncol Pract. 13: 293-300Lehmann B.D. Bauer J.A. Chen X. et al.

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

J Clin Invest. 121: 2750-2767Burstein M.D. Tsimelzon A. Poage G.M. et al.

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.

Clin Cancer Res. 21: 1688-1698Cheang M.C. Martin M. Nielsen T.O. et al.

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Oncologist. 20: 474-482Peto R. Davies C. Godwin J. et al.Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Lancet. 379: 432-444Blum J.L. Flynn P.J. Yothers G. et al.

Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

J Clin Oncol. 35: 2647-2655Hurley J. Reis I.M. Rodgers S.E. et al.

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.

Breast Cancer Res Treat. 138: 783-794Shepherd J.H. Ballman K. Polley M.C. et al.

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.

J Clin Oncol. 40: 1323-1334von Minckwitz G. Schneeweiss A. Loibl S. et al.

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Lancet Oncol. 15: 747-756Loibl S. Weber K.E. Timms K.M. et al.

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.

Ann Oncol. 29: 2341-2347Farkona S. Diamandis E.P. Blasutig I.M.

Cancer immunotherapy: the beginning of the end of cancer?.

BMC Med. 14: 73Nanda R. Liu M.C. Yau C. et al.

Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.

JAMA Oncol. 6: 676-684Schmid P. Cortes J. Pusztai L. et al.

KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer.

N Engl J Med. 382: 810-821Schmid P. Cortes J. Dent R. et al.

KEYNOTE-522 investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

N Engl J Med. 386: 556-567National Comprehensive Cancer Network (NCCN)

NCCN Clinical practice guidelines in oncology. Breast cancer version 4.2022.

Masuda N. Lee S.J. Ohtani S. et al.

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

N Engl J Med. 376: 2147-2159Joensuu H. Kellokumpu-Lehtinen P.L. Huovinen R. et al.

Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.

J Clin Oncol. 30: 11-18O'Shaughnessy J. Koeppen H. Xiao Y. et al.

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine.

Clin Cancer Res. 21: 4305-4311Natori A. Ethier J.L. Amir E. et al.

Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials.

Eur J Cancer. 77: 40-47Tutt A.N.J. Garber J.E. Kaufman B. et al.

OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

N Engl J Med. 384: 2394-2405Slamon D.J. Godolphin W. Jones L.A. et al.

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Science. 244: 707-712Korde L.A. Somerfield M.R. Carey L.A. et al.

Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline.

J Clin Oncol. 39: 1485-1505Perez E.A. Romond E.H. Suman V.J. et al.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

J Clin Oncol. 32: 3744-3752von Minckwitz G. Procter M. de Azambuja E. et al.

APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

N Engl J Med. 377: 122-131Piccart M. Procter M. Fumagalli D. et al.

APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

J Clin Oncol. 39: 1448-1457Gianni L. Eiermann W. Semiglazov V. et al.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Lancet. 375: 377-384Gianni L. Pienkowski T. Im Y.H. et al.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Lancet Oncol. 13: 25-32Guarneri V. Griguolo G. Miglietta F. et al.

Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.

ESMO Open. 7: 100433Chan A. Delaloge S. Holmes F.A. et al.ExteNET Study Group

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol. 17: 367-377Hurvitz S.A. Martin M. Symmans W.F. et al.

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.

Lancet Oncol. 19: 115-126

Metzger Filho O, Viale G, Trippa L, et al: HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. 2019 ASCO Annual Meeting. Abstract 502. Presented June 3, 2019.

Slamon D. Eiermann W. Robert N. et al.Breast Cancer International Research Group

Adjuvant trastuzumab in HER2-positive breast cancer.

N Engl J Med. 365: 1273-1283van Ramshorst M.S. van der Voort A. van Werkhoven E.D. et al.

Dutch Breast Cancer Research Group (BOOG). Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

Lancet Oncol. 19: 1630-1640van der Voort A. van Ramshorst M.S. van Werkhoven E.D. et al.

Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial.

JAMA Oncol. 7: 978-984von Minckwitz G. Huang C.S. Mano M.S. et al.

KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

N Engl J Med. 380: 617-628Spring L.M. Gupta A. Reynolds K.L. et al.

Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis.

JAMA Oncol. 2: 1477-1486Colleoni M. Viale G. Zahrieh D. et al.

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.

Clin Cancer Res. 10: 6622-6628Colleoni M. Viale G. Zahrieh D. et al.

Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy.

Ann Oncol. 19: 465-472Cataliotti L. Buzdar A.U. Noguchi S. et al.

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.

Cancer. 106: 2095-2103Smith I.E. Dowsett M. Ebbs S.R. et al.IMPACT Trialists Group

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

J Clin Oncol. 23: 5108-5116Chia Y.H. Ellis M.J. Ma C.X.

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

Br J Cancer. 103: 759-764Suman V.J. Ellis M.J. Ma C.X.

The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer.

Chin Clin Oncol. 4: 34Ellis M.J. Suman V.J. Hoog J. et al.

Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the american college of surgeons oncology group Z1031 trial (Alliance).

J Clin Oncol. 35: 1061-1069

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.

Pharmgenomics Pers Med. 7: 203-215Johnston S.R.D. Harbeck N. Hegg R. Toi M. Martin M. Shao Z.M. Zhang Q.Y. Martinez Rodriguez J.L. Campone M. Hamilton E. Sohn J. Guarneri V. Okada M. Boyle F. Neven P. Cortés J. Huober J. Wardley A. Tolaney S.M. Cicin I. Smith I.C. Frenzel M. Headley D. Wei R. San Antonio B. Hulstijn M. Cox J. O'Shaughnessy J. Rastogi P. Investigators monarchE Committee Members

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

J Clin Oncol. 38: 3987-3998Hurvitz S.A. Martin M. Press M.F. et al.

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.

Clin Cancer Res. 26: 566-580Johnston S. Puhalla S. Wheatley D. et al.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

J Clin Oncol. 37: 178-189Ellis M.J. Tao Y. Luo J. et al.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

J Natl Cancer Inst. 100: 1380-1388Khan Q.J. O’Dea A. Bardia A. et al.

Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).

J Clin Oncol. 38: 505André F. Ciruelos E. Rubovszky G. et al.

SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

N Engl J Med. 380: 1929-1940Saura C. Hlauschek D. Oliveira M. et al.

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Lancet Oncol. 20: 1226-1238Rothé F. Silva M.J. Venet D. et al.

Circulating Tumor DNA in HER2-Amplified Breast Cancer: a translational research substudy of the NeoALTTO Phase III Trial.

Clin Cancer Res. 25: 3581-3588Magbanua M.J.M. Swigart L.B. Wu H.T. et al.

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.

Ann Oncol. 32: 229-239Lipsyc-Sharf M. De Bruin E. Santos K. et al.

Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).

J Clin Oncol. 40: abstr 103

Wolf DM, Yau C, Brown-Swigart L, Hirst G, Buxton M, Paoloni M, I-SPY2 TRIAL Investigators, Olopade O, DeMichele A, Symmans F, Rugo H, Berry D, Esserman L, van t Veer L. Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer [Abstract]. In: AACR 107th Annual Meeting 2016 April 16-20, Abstract nr 859.

Whitworth P.W. Beitsch P.D. Pellicane J.V. et al.NBRST Investigators Group

Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.

JCO Precis Oncol. 6: e2100463Denkert C. von Minckwitz G. Darb-Esfahani S. et al.

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Lancet Oncol. 19: 40-50